Landiolol

beta-Adrenergic Blocker — CARDIOVASCULAR SYSTEM

Key facts

Landiolol is an onp drug in the beta-Adrenergic Blocker class catalogued in DrugCentral. It was first approved by the PMDA in 2002. Its mechanism of action is classified as Adrenergic beta1-Antagonists. DrugCentral lists 1 molecular target, including ADRB1. Recorded indications include Atrial fibrillation, Atrial flutter, Hemodynamically unstable ventricular tachycardia and Sinus tachycardia.

• Approval status: onp (first approved 2002 by the PMDA).
• Drug class: beta-Adrenergic Blocker.
• Mechanism of action: Adrenergic beta1-Antagonists.
• Molecular targets: ADRB1 (1 listed in DrugCentral).
• Indications: Atrial fibrillation, Atrial flutter, Hemodynamically unstable ventricular tachycardia, Sinus tachycardia and Supraventricular tachycardia and others.
• ATC code: C07AB14 (Beta blocking agents, selective).
• Molecular formula: C25H39N3O8; molecular weight 509.60 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (7)

• Atrial fibrillation
• Atrial flutter
• Hemodynamically unstable ventricular tachycardia
• Sinus tachycardia
• Supraventricular tachycardia
• Tachyarrhythmia
• Ventricular fibrillation

Mechanism & targets

• Mechanism of action (MoA): Adrenergic beta1-Antagonists
• Established pharmacologic class: beta-Adrenergic Blocker

Molecular targets (1)

Target	Gene	Action	Activity
Beta-1 adrenergic receptor	ADRB1	antagonist	Ki 7.00

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2016-06-29	EMA	—	AOP Orphan Pharmaceuticals AG
2002-07-05	PMDA	—	Ono Pharmaceutical Co., Ltd	Yes

ATC classification

ATC code	Therapeutic hierarchy
C07AB14	CARDIOVASCULAR SYSTEM › BETA BLOCKING AGENTS › BETA BLOCKING AGENTS › Beta blocking agents, selective

Chemical structure

• Molecular formula: C₂₅H₃₉N₃O₈
• Molecular weight: 509.60 g/mol
• CAS number: 133242-30-5
• InChIKey: WMDSZGFJQKSLLH-RBBKRZOGSA-N
• PubChem CID: 114905

CC1(C)OC[C@@H](COC(=O)CCC2=CC=C(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)C=C2)O1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Landiolol used for?

DrugCentral lists the following indications for Landiolol: Atrial fibrillation, Atrial flutter, Hemodynamically unstable ventricular tachycardia, Sinus tachycardia, Supraventricular tachycardia, Tachyarrhythmia and Ventricular fibrillation.

How does Landiolol work?

Landiolol is classified as Adrenergic beta1-Antagonists; its molecular targets in DrugCentral include ADRB1 (antagonist).

When was Landiolol first approved?

Landiolol was first approved by the PMDA in 2002.

What drug class does Landiolol belong to?

Landiolol is in the beta-Adrenergic Blocker class.

What is the chemical formula of Landiolol?

Landiolol has the molecular formula C25H39N3O8 and a molecular weight of 509.60 g/mol.

Sources

• DrugCentral drug card 1545 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1742466 — compound record and bioactivity
• PubChem CID 114905 — chemical identifiers
• DrugBank DB12212 — drug record
• FDA UNII 62NWQ924LH — substance identity
• UniProt P08588 (ADRB1) — target protein

How this page is built: methodology · editorial policy & corrections.